CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials
GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)
Disease Progression in Patients with Cystic Fibrosis Treated with Ivacaftor: Data From National US and UK Registries
Concentration of Fractional Excretion of Nitric Oxide (FENO): A Potential Airway Biomarker of Restored CFTR Function
Long-term improvement of lung clearance index in patients with mild cystic fibrosis lung disease: Does hypertonic saline play a role?
